SCHEMBL5134723

SCHEMBL5134723

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(C(F)(F)F)cc1)CC1CCCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.42
MDM2 Q00987 5/20 0.37
CRHR1 P34998 3/20 0.36
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
TSHR P16473 2/20 0.35
CCR4 P51679 2/20 0.35
BCHE P06276 2/20 0.35
CYP3A4 P08684 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR7 P34969 1/20 0.35
CKS1B P61024 1/20 0.34
SKP1 P63208 1/20 0.34
SKP2 Q13309 1/20 0.34
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136228 0.93 C5AR1 (0.42) C5AR1CRHR1KDM4EALDH1A1TSHR
SCHEMBL650021 0.92 C5AR1 (0.41) C5AR1CRHR1KDM4EALDH1A1TSHR
SCHEMBL5135713 0.92 C5AR1 (0.44) C5AR1KDM4EALDH1A1TSHRCYP3A4
SCHEMBL5137864 0.92 C5AR1 (0.44) C5AR1KDM4EALDH1A1TSHRBCHE
SCHEMBL5137114 0.91 C5AR1 (0.43) C5AR1CRHR1KDM4EALDH1A1TSHR
SCHEMBL5134999 0.91 C5AR1 (0.44) C5AR1KDM4EALDH1A1TSHRBCHE
SCHEMBL5134910 0.91 C5AR1 (0.44) C5AR1CRHR1KDM4EALDH1A1TSHR
SCHEMBL650435 0.91 C5AR1 (0.42) C5AR1CRHR1CCR4
SCHEMBL5136197 0.90 C5AR1 (0.40) C5AR1CRHR1KDM4EALDH1A1TSHR
SCHEMBL5135678 0.90 C5AR1 (0.43) C5AR1KDM4EALDH1A1TSHRBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed